DuoHexaBody‑CD37 triggers complement‑independent cytotoxic signaling in diffuse large B-cell lymphoma (DLBCL), revealing therapeutic pathways that can be exploited to enhance tumor cell killing through targeted combination strategies.
The Verdict
ClassificationLikely Human
ConfidenceMedium confidence
Analyzedtext
Community Verdict
Sign in to vote
Be the first to vote on this assessment.
Embed Badge
Add this badge to your site to show the AI classification for this content.
[](https://real.press/content/03c2d1e3-5826-4d0c-af0d-9af2142e7774)